Bioequivalence and Bioavailability Forum 10:59 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

carryover effect in endogenous substances [Regulatives / Guidelines]

posted by Ramesh Ramalingam - India, 2018-08-08 07:29  - Posting: # 19159
Views: 443

Dear Helmut,

As per previous discussion. We con't directly assess the carry-over effect for endogenous substances. As per USFDA regulatory requirement we have to approach the concept of 5% cmax for endogenous substances also https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM234960.pdf. but they are not clearly telling about how to approach these concept for endogenous substances.

Kindly share your suggestions about to below statements.
When dealing with endogenous substances, the presence of carry-over effects is very difficult to quantify. Therefore to find a proof of absence or presence of carryover effect in endogenous substances, the pre-dose (baseline) drug concentrations for Period 1 should compared to the pre-dose concentrations for Period 2. Thus, previous period average pre-dose concentration should be subtracted with subsequent period average pre-dose concentration after that the resulted values should compare with 5% of cmax. Based on this we can ensure the carry over effect occurred or not in period 1 or in subsequent period.


Regards,
Ramesh.R

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,782 posts in 4,002 threads, 1,256 registered users;
online 18 (0 registered, 18 guests [including 15 identified bots]).

[…] our greatest mistake would be to forget that data
is used for serious decisions in the very real world,
and bad information causes suffering and death.    Ben Goldacre

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed